Staidson Biopharmaceuticals Hits Day High with 3.77% Intraday Surge

Staidson (Beijing) Biopharmaceuticals Co., Ltd. has experienced a notable increase of 3.77% on March 6, 2026, reaching an intraday high of CNY 26.17. This performance stands in contrast to the China Shanghai Composite, which saw a modest gain of 0.38% on the same day. Despite today's positive movement, Staidson's performance over the past week has declined by 2.31%, and it has faced a more significant drop of 7.08% over the past month. However, the company has shown remarkable growth over the past year, with a staggering increase of 245.13%, significantly outpacing the China Shanghai Composite's 21.98% gain. Staidson operates within the Pharmaceuticals & Biotechnology sector and holds a market capitalization of CNY 12,241 million. While the stock has demonstrated impressive long-term performance, it is important to note that the company has reported losses and has a negative net worth, raising concerns about its financial health. The company’s return on equity stands at -20.24%, indicating challenges in management efficiency.